Avere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal

Avere Therapeutics has burst onto the scene by securing a public listing via a reverse merger with NextCure, while stocking a pipeline with an IL-23 drug from Hansoh Pharmaceutical.